Little is known about the heritability of chemotherapy activity or the identity of genes that may enable the individualization of cancer chemotherapy. Although numerous genes are likely to influence chemotherapy response, current candidate gene-based pharmacogenetics approaches require a priori knowledge and the selection of a small number of candidate genes for hypothesis testing. In this study, an ex vivo familial genetics strategy using lymphoblastoid cells derived from Centre d'Etude du Polymorphisme Humain reference pedigrees was used to discover genetic determinants of chemotherapy cytotoxicity. Cytotoxicity to the mechanistically distinct chemotherapy agents 5-fluorouracil and docetaxel were shown to be heritable traits, with heritability values ranging from 0.26 to 0.65 for 5-fluorouracil and 0.21 to 0.70 for docetaxel, varying with dose. Genome-wide linkage analysis was also used to map a quantitative trait locus influencing the cellular effects of 5-fluorouracil to chromosome 9q13-q22 [logarithm of odds (LOD) ؍ 3.44], and two quantitative trait loci influencing the cellular effects of docetaxel to chromosomes 5q11-21 (LOD ؍ 2.21) and 9q13-q22 (LOD ؍ 2.73). Finally, 5-fluorouracil and docetaxel were shown to cause apoptotic cell death involving caspase-3 cleavage in Centre d'Etude du Polymorphisme Humain lymphoblastoid cells. This study identifies genomic regions likely to harbor genes important for chemotherapy cytotoxicity using genome-wide linkage analysis in human pedigrees and provides a widely applicable strategy for pharmacogenomic discovery without the requirement for a priori candidate gene selection.
Significant interpatient variability in response to chemotherapy is consistently observed across patient populations (1, 2). Initial candidate gene evaluations of severe toxicity to chemotherapeutic agents have revealed specific examples of pharmacogenetically relevant single-nucleotide polymorphisms (3, 4), and previous studies of twins detailed a substantial influence of inheritance on general measures of hepatic drug metabolism (5, 6). However, little is known about the heritability of chemotherapy activity and current candidate gene strategies require the a priori selection of individual candidates from among the potentially numerous genes that may regulate the action of a drug (2). Unbiased genome-wide approaches are needed, but traditional methods for assessing genetic contribution (e.g., family studies of patients or volunteers) are obstructed for chemotherapy outcomes due to the rarity of simultaneous occurrence of a specific tumor type among family members and the unsuitability of these agents for use in normal volunteer subjects. Whole-genome association studies in clinical populations have a theoretical basis as a strategy for the discovery of markers influencing drug response (7,8); however, such studies are currently limited by sample size, the availability of relevant populations, and the expense of genotyping (9, 10).Therefore, an ex vivo familial genetics strategy involving l...